Taking low-dose aspirin on regular basis has been connected to lower risk of developing ovarian cancer, according to an analysis of data from thousands of women in the United States.
A 23 percent lower risk of ovarian cancer was discovered in women who reported taking up to 100 milligrams of aspirin, compared to those who had taken none.
Though the researchers did not discover any links between “standard-dose” aspirin use (325 milligrams) and ovarian cancer risk.
A paper on this study — which was led by the Harvard T.H. Chan School of Public Health in Boston, MA — is to appear in the JAMA Oncology journal.
Lead study author, Dr. Mollie E. Barnard at the Harvard T.H. Chan School of Public Health, said; “Our findings emphasize that research on aspirin use and cancer risk must consider aspirin dose.”
Dr. Barnard and her colleagues noted that there are few modifiable risk factors for ovarian cancer. According to the team; “There is increasing evidence that inflammation contributes to ovarian cancer”.
The team ran a study on detailed exposure data to assess whether timing and patterns of analgesic use are linked with risk of ovarian cancer.
The study data came from a total of 205,498 women — 1,054 of whom developed ovarian cancer. The women had reported use of standard and low-dose aspirin, other NSAIDs, and acetaminophen. The reports gave details of timing, pattern, frequency, and duration of use, including numbers of tablets ingested.
The analysis showed a link between “recent low-dose aspirin use” and a reduced risk of ovarian cancer, but there was no link for standard-dose use. However, longer-term use of low-dose aspirin was not linked to further risk reduction.
There was a suggestion, however, that taking at least 10 tablets per week of non-aspirin NSAIDs such as naproxen and ibuprofen for several years could be linked to higher risk of ovarian cancer.
The researchers noted that further research needs to be conducted.